IPO
Biofidelity Ltd announces it has secured £0.75 million seed financing, following its formation earlier this year.
Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.
Massachusetts Life Sciences Center awards funding to support early-stage growth across major sectors
MLSC’s Milestone Achievement Program awards more than $1.9 million to 10 companies representing all major life sciences sectors
Robocath announces that it has raised €5 million to support the rollout of its robotic platform in strategic European target markets.
Forbion announces that it has participated in a £100 million Series B financing of Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies.
Financing will support continued clinical development of gene therapies and surgical delivery systems for retinal diseases
Achilles Therapeutics announces it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.
Santhera Pharmaceuticals reports first half-year results as of June 30, 2019, and provides an update on its pipeline and strategic focus.
Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing SkylineDx’ market potential of over $1 billion annually based on their current progress in the melanoma field.
A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited are pleased to announce that its interim results for the period ended 30 June 2019
PRESS RELEASES